Improved Flexor Spasticity in Patients with Chronic Stroke Using a Dynamic Wrist-Hand Stretching Device: A Pilot Randomized Controlled Trial.

NeuroRehabilitationJul 3, 2026 (epub)
Clinical ResearchPhysical Medicine & Rehabilitation

Jacob Kim, Justin Kim, Philbert Chen et al.

✦ AI-curated · Sources linked

In 30 seconds

This pilot randomized controlled trial evaluated the Hand Stretcher®, a dynamic stretching device, in 30 chronic stroke patients with mild upper limb weakness and spasticity. The intervention group showed significant reductions in wrist and finger flexor spasticity after two months of use, while no serious adverse events were reported.

Key findings

  • The intervention group experienced significant reductions in wrist and finger flexor spasticity.
  • Improvements in Manual Functional Test and Brunnstrom stage were observed at the end of the intervention.
  • No significant changes in wrist or finger extensor strength were noted in either group.

Why it matters

Effective management of spasticity is crucial for improving quality of life and functional independence in stroke patients. This study suggests that a dynamic stretching device may enhance rehabilitation outcomes.

Source

PubMed · PMID 42396838

Published in NeuroRehabilitation. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Physical Medicine & Rehabilitation

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.